Xilio Therapeutics, Inc. (XLO)

NASDAQ: XLO · IEX Real-Time Price · USD
0.720
+0.011 (1.61%)
At close: Mar 1, 2024, 4:00 PM
0.774
+0.053 (7.37%)
After-hours: Mar 1, 2024, 7:59 PM EST
1.61%
Market Cap 19.83M
Revenue (ttm) n/a
Net Income (ttm) -81.22M
Shares Out 27.53M
EPS (ttm) -2.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 566,910
Open 0.780
Previous Close 0.709
Day's Range 0.720 - 0.850
52-Week Range 0.490 - 3.670
Beta -0.38
Analysts Strong Buy
Price Target 7.00 (+871.68%)
Earnings Date Mar 12, 2024

About XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquart... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 22, 2021
Employees 81
Stock Exchange NASDAQ
Ticker Symbol XLO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for XLO stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(871.68% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo...

4 days ago - GlobeNewsWire

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo...

4 weeks ago - GlobeNewsWire

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed to date

7 weeks ago - GlobeNewsWire

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Phase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC)

3 months ago - GlobeNewsWire

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Demonstrated initial clinical validation of tumor-selective activation technology for both XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and XTX202, a tumor-activated, beta-gamma IL-2

4 months ago - GlobeNewsWire

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, ...

4 months ago - GlobeNewsWire

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo...

4 months ago - GlobeNewsWire

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies f...

5 months ago - GlobeNewsWire

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D.

Martin Huber, M.D., to leave Xilio Therapeutics and remain an advisor Martin Huber, M.D., to leave Xilio Therapeutics and remain an advisor

6 months ago - GlobeNewsWire

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies f...

6 months ago - GlobeNewsWire

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®), in patients with microsatellit...

7 months ago - GlobeNewsWire

Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer

WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo...

7 months ago - GlobeNewsWire

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer

10 months ago - GlobeNewsWire

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK, PD, and anti-tumor activity data for XTX101, a tumor-activated, Fc-enhanced ant...

10 months ago - GlobeNewsWire

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, t...

11 months ago - GlobeNewsWire

Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results

Initial clinical data from XTX101, XTX202 and XTX301 clinical trials anticipated in 2023

1 year ago - GlobeNewsWire

Xilio Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, to...

1 year ago - GlobeNewsWire

Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, to...

1 year ago - GlobeNewsWire

Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, to...

1 year ago - GlobeNewsWire

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, to...

1 year ago - GlobeNewsWire

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with ...

1 year ago - GlobeNewsWire

Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next' Summit

WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, to...

1 year ago - GlobeNewsWire

Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, t...

1 year ago - GlobeNewsWire

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, Joins as a Strategic Advisor John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, Joins as a Strategic Adviso...

1 year ago - GlobeNewsWire

Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, t...

1 year ago - GlobeNewsWire